Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralsetinib vs SOC in RET-Mutated Medullary Thyroid Cancer
NCT04760288Phase 3Withdrawn
- Sponsor
- Roche
- Start
- Nov 2023
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pralsetinib in Medullary Thyroid Cancer (MTC), sponsored by Roche. Planned start Nov 2023; status: withdrawn.
02
Drugs
pralsetinib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT04760288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04760288.